[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-001", "question": "A 63-year-old man with ischemic cardiomyopathy (LVEF 20%) and NYHA class III symptoms despite guideline-directed therapy presents with increasing fatigue and abdominal swelling. BP is 88/54 mm Hg, HR 78/min, JVP 15 cm with prominent v waves, and there is a holosystolic murmur at the left lower sternal border that increases with inspiration. Echo shows severe functional tricuspid regurgitation with right atrial and RV dilation, TAPSE 1.0 cm, RV fractional area change 25%, PASP 42 mm Hg, and no significant left-sided valvular disease. Coronary anatomy is unchanged from prior and not revascularizable. He is in sinus rhythm and not a heart transplant candidate. After optimization of diuretics, he remains symptomatic. Which management strategy is most appropriate to improve outcomes?", "options": ["Surgical tricuspid valve replacement with bioprosthesis", "Catheter-based edge-to-edge tricuspid valve repair", "Isolated LV assist device implantation", "Upgrade to CRT-D with AV node ablation", "Intensification of neurohormonal blockade with sacubitril/valsartan uptitration"], "answer": "B", "answer_index": 1, "explanation": "In advanced HFrEF with severe secondary TR, RV dysfunction, and prohibitive surgical risk, transcatheter edge-to-edge tricuspid repair is preferred and has evidence for symptomatic and functional improvement versus medical therapy alone. Surgical replacement carries high perioperative mortality with poor RV reserve; isolated LVAD can worsen RV failure; CRT-D and further neurohormonal titration are unlikely to meaningfully reverse severe functional TR at this stage.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include severe functional tricuspid regurgitation (TR) with RV dilation and dysfunction (TAPSE 1.0 cm, FAC 25%), advanced HFrEF (LVEF 20%, NYHA III), persistent symptoms despite GDMT and diuretics, hypotension (BP 88/54), sinus rhythm, non-revascularizable coronaries, and ineligibility for transplant—pointing to a high-risk profile favoring minimally invasive TR intervention over surgery or advanced devices. Main logical issues: none; the vignette provides sufficient discriminating details (e.g., RV impairment, no left valvular issues, sinus rhythm) to eliminate alternatives without contradictions or underspecification, supporting B as uniquely best. Main medical accuracy issues: none; aligns with current guidelines (e.g., TRILUMINATE trial evidence for transcatheter edge-to-edge repair in high-risk secondary TR with RV dysfunction, improving symptoms vs. medical therapy). Surgical replacement risks high mortality in poor RV reserve; isolated LVAD may exacerbate RV failure; CRT-D lacks indication without dyssynchrony; further ARNI uptitration is limited by hypotension and unlikely to reverse severe TR. Minimal fix: none required; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include severe functional tricuspid regurgitation (TR) with RV dilation and dysfunction (TAPSE 1.0 cm, FAC 25%), advanced HFrEF (LVEF 20%, NYHA III), persistent symptoms despite GDMT and diuretics, hypotension (BP 88/54), sinus rhythm, non-revascularizable coronaries, and ineligibility for transplant—pointing to a high-risk profile favoring minimally invasive TR intervention over surgery or advanced devices. Main logical issues: none; the vignette provides sufficient discriminating details (e.g., RV impairment, no left valvular issues, sinus rhythm) to eliminate alternatives without contradictions or underspecification, supporting B as uniquely best. Main medical accuracy issues: none; aligns with current guidelines (e.g., TRILUMINATE trial evidence for transcatheter edge-to-edge repair in high-risk secondary TR with RV dysfunction, improving symptoms vs. medical therapy). Surgical replacement risks high mortality in poor RV reserve; isolated LVAD may exacerbate RV failure; CRT-D lacks indication without dyssynchrony; further ARNI uptitration is limited by hypotension and unlikely to reverse severe TR. Minimal fix: none required; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-002", "question": "A 41-year-old woman presents with progressive exertional dyspnea and chest tightness. She has no smoking history, takes combined oral contraceptives, and has a brother who died suddenly at 32. Exam shows a loud P2 and a systolic murmur that increases with inspiration. ECG shows right axis deviation and incomplete RBBB. Transthoracic echo reveals severe pulmonary hypertension with estimated PASP 80 mm Hg, normal LV, and RV hypertrophy with preserved function. V/Q scan is normal. Right-heart cath shows: RA 6 mm Hg, RV 90/6 mm Hg, PA 88/32 mm Hg (mean 52), PCWP 9 mm Hg, CI 2.1 L/min/m², PVR 10 Wood units. Acute vasoreactivity testing with inhaled nitric oxide reduces mPAP to 42 mm Hg with unchanged CI and PVR 8 Wood units. Genetic testing is pending. What is the most appropriate initial long-term therapy?", "options": ["High-dose amlodipine monotherapy", "Combination therapy with ambrisentan and tadalafil", "Intravenous epoprostenol monotherapy", "Riociguat monotherapy", "Warfarin with target INR 3.0-4.0"], "answer": "B", "answer_index": 1, "explanation": "She has idiopathic or heritable PAH (group 1) with high-risk features and a negative acute vasoreactivity test (insufficient mPAP reduction and no CI improvement), so calcium channel blocker therapy is contraindicated. Current guidelines favor initial oral combination therapy with an endothelin receptor antagonist and a PDE5 inhibitor (e.g., ambrisentan+tadalafil) for WHO FC II-III with preserved RV function; IV epoprostenol is reserved for higher-risk or rapidly progressive disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include progressive dyspnea, family history of sudden death suggesting heritable PAH, clinical signs of pulmonary hypertension (loud P2, inspiratory-augmented systolic murmur), ECG evidence of right heart strain, echo confirming severe PH with RV hypertrophy and preserved function, normal V/Q scan ruling out CTEPH, RHC showing pre-capillary PH (high PVR 10 WU, normal PCWP), and negative acute vasoreactivity (mPAP reduction from 52 to 42 mmHg without CI improvement, failing criteria for positive response: absolute mPAP ≤40 mmHg with increased/unchanged CO). These support Group 1 PAH diagnosis, contraindicating CCB (A), reserving IV epoprostenol (C) for high-risk cases, making riociguat (D) unsuitable as monotherapy for PAH (better for CTEPH), and warfarin (E) not initial therapy. Combo ERA + PDE5i (B) aligns with guidelines for initial therapy in low-intermediate risk PAH with preserved RV. No logical issues: stem allows unique discrimination without contradictions or underspecification. No medical accuracy issues: reflects current ESC/ERS guidelines on PAH classification, vasoreactivity testing, and risk-stratified management. Minimal fix: None needed, as item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include progressive dyspnea, family history of sudden death suggesting heritable PAH, clinical signs of pulmonary hypertension (loud P2, inspiratory-augmented systolic murmur), ECG evidence of right heart strain, echo confirming severe PH with RV hypertrophy and preserved function, normal V/Q scan ruling out CTEPH, RHC showing pre-capillary PH (high PVR 10 WU, normal PCWP), and negative acute vasoreactivity (mPAP reduction from 52 to 42 mmHg without CI improvement, failing criteria for positive response: absolute mPAP ≤40 mmHg with increased/unchanged CO). These support Group 1 PAH diagnosis, contraindicating CCB (A), reserving IV epoprostenol (C) for high-risk cases, making riociguat (D) unsuitable as monotherapy for PAH (better for CTEPH), and warfarin (E) not initial therapy. Combo ERA + PDE5i (B) aligns with guidelines for initial therapy in low-intermediate risk PAH with preserved RV. No logical issues: stem allows unique discrimination without contradictions or underspecification. No medical accuracy issues: reflects current ESC/ERS guidelines on PAH classification, vasoreactivity testing, and risk-stratified management. Minimal fix: None needed, as item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-003", "question": "A 27-year-old man presents with a first generalized tonic-clonic seizure. MRI brain with and without contrast is normal. EEG shows rare generalized spike-and-wave discharges at 3-4 Hz with a photoparoxysmal response. Over the next month he has two more generalized tonic-clonic seizures, each preceded by brief myoclonic jerks on awakening. He drinks socially and works as a software engineer. He and his partner plan to conceive in the next year, and he wants to avoid cognitive side effects. Which antiepileptic monotherapy is most appropriate?", "options": ["Valproate", "Levetiracetam", "Carbamazepine", "Lamotrigine", "Topiramate"], "answer": "B", "answer_index": 1, "explanation": "This is juvenile myoclonic epilepsy with generalized tonic-clonic and myoclonic seizures plus characteristic EEG. While valproate is highly effective, its teratogenicity, metabolic effects, and cognitive risks make it less desirable in a young adult planning pregnancy with a partner and with concerns about adverse effects. Levetiracetam is effective for generalized epilepsies, has a favorable cognitive profile, and minimal drug interactions; carbamazepine can worsen generalized seizures, and lamotrigine/topiramate are less predictably effective for myoclonus.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include: 27-year-old male with first GTCS, normal MRI, EEG showing generalized 3-4 Hz spike-and-wave with photoparoxysmal response, subsequent GTCS preceded by myoclonic jerks on awakening, social drinking, software engineer, plans to conceive with partner, desires to avoid cognitive side effects. These point to juvenile myoclonic epilepsy (JME), requiring monotherapy effective for generalized/myoclonic seizures with favorable cognitive profile and minimal teratogenic risk. Levetiracetam (B) fits as it's effective for JME, has good cognitive tolerability, and low interaction risk. Alternatives: Valproate (A) is effective but has cognitive/metabolic risks and potential paternal teratogenicity concerns; Carbamazepine (C) may exacerbate generalized seizures; Lamotrigine (D) and Topiramate (E) are less optimal for myoclonus control, with topiramate risking cognitive effects. No main logical issues; stem allows clear discrimination without contradictions or underspecification. Main medical accuracy issues: Minor—teratogenicity emphasis on valproate is somewhat overstated for a male patient, as primary risks are maternal, though paternal fertility/epigenetic effects exist; overall aligns with guidelines favoring levetiracetam as alternative to valproate in JME for side effect concerns. Minimal fix: No fix required; optionally rephrase rationale to focus more on male-specific valproate risks.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include: 27-year-old male with first GTCS, normal MRI, EEG showing generalized 3-4 Hz spike-and-wave with photoparoxysmal response, subsequent GTCS preceded by myoclonic jerks on awakening, social drinking, software engineer, plans to conceive with partner, desires to avoid cognitive side effects. These point to juvenile myoclonic epilepsy (JME), requiring monotherapy effective for generalized/myoclonic seizures with favorable cognitive profile and minimal teratogenic risk. Levetiracetam (B) fits as it's effective for JME, has good cognitive tolerability, and low interaction risk. Alternatives: Valproate (A) is effective but has cognitive/metabolic risks and potential paternal teratogenicity concerns; Carbamazepine (C) may exacerbate generalized seizures; Lamotrigine (D) and Topiramate (E) are less optimal for myoclonus control, with topiramate risking cognitive effects. No main logical issues; stem allows clear discrimination without contradictions or underspecification. Main medical accuracy issues: Minor—teratogenicity emphasis on valproate is somewhat overstated for a male patient, as primary risks are maternal, though paternal fertility/epigenetic effects exist; overall aligns with guidelines favoring levetiracetam as alternative to valproate in JME for side effect concerns. Minimal fix: No fix required; optionally rephrase rationale to focus more on male-specific valproate risks.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-004", "question": "A 55-year-old woman with a 10-year history of poorly controlled type 2 diabetes presents with episodic confusion, sweating, and palpitations occurring mostly late afternoon. Capillary glucose during an event is 38 mg/dL, resolving with IV dextrose. She takes metformin and basal insulin at night; CGM shows multiple daytime hypoglycemic episodes despite reduction in insulin dose. She denies sulfonylurea use or alcohol. Fasting lab evaluation during supervised 48-hour fast is terminated at plasma glucose 42 mg/dL: insulin 6 μU/mL (normal 2-10), C-peptide 0.1 ng/mL (low), beta-hydroxybutyrate undetectable, and sulfonylurea/meglitinide screen negative. CT of the pancreas is normal. What is the most likely diagnosis?", "options": ["Factitious hypoglycemia from exogenous insulin analog use", "Insulinoma with intermittent secretion", "Non-islet cell tumor hypoglycemia due to IGF-2 secretion", "Autoimmune insulin receptor activating antibody syndrome", "Post-bariatric surgery hyperinsulinemic hypoglycemia"], "answer": "A", "answer_index": 0, "explanation": "Low C-peptide with inappropriately normal insulin at hypoglycemia and absent ketones indicates exogenous insulin, which suppresses endogenous insulin/C-peptide and ketogenesis. Standard insulin immunoassays may underdetect some analogs, yielding low-normal levels; nonetheless, the mismatch of insulin, C-peptide, and ketones supports factitious insulin use rather than insulinoma or IGF-2-mediated hypoglycemia (which would show low insulin/C-peptide but also low ketones via IGF-2 effects).", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: C (primary; secondary U leading to N). Verdict on keyed answer: No defensible answer. Key stem clues that drive (or fail to drive) a unique best answer: Episodic daytime hypoglycemia in T2DM patient on basal insulin, with supervised 48-hour fast showing glucose 42 mg/dL, insulin 6 μU/mL (normal 2-10, inappropriate for hypoglycemia), low C-peptide 0.1 ng/mL, undetectable beta-hydroxybutyrate, negative sulfonylurea screen, normal pancreatic CT. These labs suggest exogenous insulin (mismatched insulin/C-peptide, suppressed ketones), but 'supervised' fast implies no opportunity for administration. Main logical issue(s): Internal contradiction (C) - supervised fast precludes exogenous insulin use, making factitious hypoglycemia (A) implausible despite fitting labs; this renders the item incoherent and underspecified (U) regarding supervision details, leading to no defensible answer (N) as alternatives mismatch (B: expects high C-peptide; C: expects suppressed insulin <2-3 μU/mL; D: rare, expects low insulin; E: no surgical history, expects high C-peptide). Main medical accuracy issue(s): Lab pattern accurately reflects exogenous insulin effects, including potential underdetection of analogs; suppressed ketones correct for both exogenous and NICTH, but scenario unrealistically combines supervision with factitious cause without nuance. Minimal fix: Edit stem to remove 'supervised' from the fast description, allowing A as unambiguous best without contradiction.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (primary; secondary U leading to N). Verdict on keyed answer: No defensible answer. Key stem clues that drive (or fail to drive) a unique best answer: Episodic daytime hypoglycemia in T2DM patient on basal insulin, with supervised 48-hour fast showing glucose 42 mg/dL, insulin 6 μU/mL (normal 2-10, inappropriate for hypoglycemia), low C-peptide 0.1 ng/mL, undetectable beta-hydroxybutyrate, negative sulfonylurea screen, normal pancreatic CT. These labs suggest exogenous insulin (mismatched insulin/C-peptide, suppressed ketones), but 'supervised' fast implies no opportunity for administration. Main logical issue(s): Internal contradiction (C) - supervised fast precludes exogenous insulin use, making factitious hypoglycemia (A) implausible despite fitting labs; this renders the item incoherent and underspecified (U) regarding supervision details, leading to no defensible answer (N) as alternatives mismatch (B: expects high C-peptide; C: expects suppressed insulin <2-3 μU/mL; D: rare, expects low insulin; E: no surgical history, expects high C-peptide). Main medical accuracy issue(s): Lab pattern accurately reflects exogenous insulin effects, including potential underdetection of analogs; suppressed ketones correct for both exogenous and NICTH, but scenario unrealistically combines supervision with factitious cause without nuance. Minimal fix: Edit stem to remove 'supervised' from the fast description, allowing A as unambiguous best without contradiction.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-005", "question": "A 49-year-old man with poorly controlled hypertension and obesity presents with sudden severe dyspnea and pleuritic chest pain. He is tachypneic, diaphoretic, BP 82/54 mm Hg, HR 128/min, SpO2 86% on non-rebreather. JVP is 12 cm, lungs are clear. Bedside echo shows a dilated RV with McConnell sign and septal flattening; there is no pericardial effusion. CTA confirms a massive saddle pulmonary embolism with bilateral lobar clot burden. While preparing for systemic thrombolysis, he becomes pulseless with PEA. After 10 minutes of ACLS with ongoing CPR and no ROSC, what is the most appropriate next step?", "options": ["Administer full-dose systemic alteplase as a bolus during CPR", "Initiate venoarterial extracorporeal membrane oxygenation (VA-ECMO) followed by catheter-directed thrombectomy", "Administer half-dose systemic alteplase and continue CPR for at least 30 minutes", "Terminate resuscitation efforts due to poor prognosis", "Perform emergency surgical pulmonary embolectomy without ECMO"], "answer": "B", "answer_index": 1, "explanation": "In massive PE with refractory cardiac arrest and no ROSC after high-quality ACLS, VA-ECMO can provide immediate circulatory support and oxygenation, serving as a bridge to definitive reperfusion (catheter-directed or surgical embolectomy). Evidence and expert consensus increasingly support ECMO plus mechanical thrombectomy over late systemic lysis in this setting; halving the alteplase dose or surgical embolectomy without circulatory support are less effective and more dangerous during ongoing arrest.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Massive saddle PE confirmed by CTA, RV dilation with McConnell sign and septal flattening on echo, refractory PEA arrest after 10 minutes of ACLS with no ROSC, while preparing for systemic thrombolysis. These indicate high-risk PE with hemodynamic collapse requiring advanced circulatory support and definitive reperfusion. Main logical issue(s), if any: None; the vignette provides sufficient details to discriminate B as uniquely best, with alternatives inferior due to risks (A: full-dose lysis bleeding during CPR), inefficacy (C: half-dose suboptimal), futility (D: premature termination), or danger (E: surgery without support). Main medical accuracy issue(s), if any: None; aligns with current guidelines (AHA/ESC) supporting VA-ECMO in refractory PE arrest as a bridge to catheter-directed thrombectomy, over systemic thrombolysis which carries higher bleeding risk in prolonged CPR. The teaching point reflects emerging consensus on ECMO in tertiary settings for massive PE with no ROSC. Minimal fix: None needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Massive saddle PE confirmed by CTA, RV dilation with McConnell sign and septal flattening on echo, refractory PEA arrest after 10 minutes of ACLS with no ROSC, while preparing for systemic thrombolysis. These indicate high-risk PE with hemodynamic collapse requiring advanced circulatory support and definitive reperfusion. Main logical issue(s), if any: None; the vignette provides sufficient details to discriminate B as uniquely best, with alternatives inferior due to risks (A: full-dose lysis bleeding during CPR), inefficacy (C: half-dose suboptimal), futility (D: premature termination), or danger (E: surgery without support). Main medical accuracy issue(s), if any: None; aligns with current guidelines (AHA/ESC) supporting VA-ECMO in refractory PE arrest as a bridge to catheter-directed thrombectomy, over systemic thrombolysis which carries higher bleeding risk in prolonged CPR. The teaching point reflects emerging consensus on ECMO in tertiary settings for massive PE with no ROSC. Minimal fix: None needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-006", "question": "A 38-year-old woman presents with progressive proximal muscle weakness over 6 weeks, difficulty climbing stairs, and new-onset dry cough. Exam shows 4/5 strength in hip flexors and shoulder abductors, Gottron papules over MCP joints, and a faint \"mechanic's hands\" rash. CK is 700 IU/L (mildly elevated). High-resolution CT shows bilateral peripheral ground-glass opacities and traction bronchiectasis in lower lobes. Pulmonary function tests show FVC 60% predicted, DLCO 35% predicted, and an FVC/DLCO ratio >1.6. ANA is positive 1:320 speckled. Which specific autoantibody, if present, would indicate the highest risk of rapidly progressive interstitial lung disease requiring aggressive early immunosuppression?", "options": ["Anti-Jo-1 (histidyl-tRNA synthetase)", "Anti-Mi-2", "Anti-MDA5", "Anti-SRP", "Anti-TIF1-γ"], "answer": "C", "answer_index": 2, "explanation": "Anti-MDA5 dermatomyositis is characteristically associated with rapidly progressive, often fatal ILD, even with only mild myositis or CK elevation, and warrants early aggressive combination immunosuppression. Anti-Jo-1 also associates with ILD but usually more indolent; anti-Mi-2 is linked to classic dermatomyositis with good prognosis; anti-SRP to necrotizing myopathy; anti-TIF1-γ to malignancy-associated dermatomyositis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include progressive proximal weakness, Gottron papules, mechanic's hands rash, mildly elevated CK (700 IU/L), dry cough, HRCT with bilateral peripheral ground-glass opacities and traction bronchiectasis, PFTs showing restrictive pattern (FVC 60%, DLCO 35%) with FVC/DLCO >1.6, and positive speckled ANA 1:320. These suggest dermatomyositis (DM) with interstitial lung disease (ILD), where anti-MDA5 antibody indicates highest risk for rapidly progressive, potentially fatal ILD despite mild myositis, necessitating early aggressive immunosuppression. The stem provides sufficient discriminating details like mechanic's hands and subacute onset with mild CK to favor anti-MDA5 over others. No main logical issues; the vignette is internally consistent, supports a single best answer (C), and the key matches it without requiring unstated assumptions. No main medical accuracy issues; aligns with current rheumatology guidelines (e.g., EULAR/ACR) associating anti-MDA5 DM with amyopathic features and refractory ILD, while anti-Jo-1 links to more indolent ILD in antisynthetase syndrome, anti-Mi-2 to favorable-prognosis classic DM, anti-SRP to severe myopathy, and anti-TIF1-γ to paraneoplastic DM. Minimal fix: None needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include progressive proximal weakness, Gottron papules, mechanic's hands rash, mildly elevated CK (700 IU/L), dry cough, HRCT with bilateral peripheral ground-glass opacities and traction bronchiectasis, PFTs showing restrictive pattern (FVC 60%, DLCO 35%) with FVC/DLCO >1.6, and positive speckled ANA 1:320. These suggest dermatomyositis (DM) with interstitial lung disease (ILD), where anti-MDA5 antibody indicates highest risk for rapidly progressive, potentially fatal ILD despite mild myositis, necessitating early aggressive immunosuppression. The stem provides sufficient discriminating details like mechanic's hands and subacute onset with mild CK to favor anti-MDA5 over others. No main logical issues; the vignette is internally consistent, supports a single best answer (C), and the key matches it without requiring unstated assumptions. No main medical accuracy issues; aligns with current rheumatology guidelines (e.g., EULAR/ACR) associating anti-MDA5 DM with amyopathic features and refractory ILD, while anti-Jo-1 links to more indolent ILD in antisynthetase syndrome, anti-Mi-2 to favorable-prognosis classic DM, anti-SRP to severe myopathy, and anti-TIF1-γ to paraneoplastic DM. Minimal fix: None needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-007", "question": "A 72-year-old man with long-standing COPD (FEV1 35% predicted), chronic hypercapnia, and recent admission for an acute exacerbation requiring noninvasive ventilation is evaluated 3 weeks after discharge. He continues to have daytime somnolence and morning headaches despite resolution of wheeze and normalization of oxygenation on 2 L/min nasal cannula. ABG on his usual oxygen shows pH 7.37, PaCO2 58 mm Hg, PaO2 70 mm Hg, HCO3- 33 mEq/L. Overnight oximetry reveals sustained hypoventilation with episodic desaturations but no significant obstructive apneas. He is adherent to inhaled therapy and pulmonary rehab. What is the most appropriate next step in chronic management to improve mortality?", "options": ["Increase long-term oxygen therapy to maintain PaO2 >80 mm Hg", "Start nocturnal noninvasive ventilation with targeted normalization of PaCO2", "Add chronic low-dose oral prednisone", "Begin acetazolamide at night to stimulate ventilation", "Switch to high-flow nasal cannula at home during sleep"], "answer": "B", "answer_index": 1, "explanation": "In stable COPD with chronic hypercapnic respiratory failure, particularly after a hypercapnic exacerbation, nocturnal noninvasive ventilation targeting PaCO2 reduction reduces mortality and hospitalizations. Increasing oxygen can worsen hypercapnia; chronic steroids confer harm; acetazolamide has limited long-term data; home high-flow therapy improves comfort but lacks robust mortality benefit compared with NIV in this phenotype.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include severe COPD with FEV1 35% predicted, chronic hypercapnia (PaCO2 58 mm Hg, compensated pH 7.37, HCO3- 33 mEq/L), recent hypercapnic exacerbation requiring NIV, persistent daytime somnolence and morning headaches, sustained hypoventilation on overnight oximetry without obstructive apneas, and adherence to standard therapies with PaO2 70 mm Hg on 2 L/min oxygen. These point to chronic hypercapnic respiratory failure needing ventilatory support to improve mortality. Main logical issues: none; the stem provides sufficient discriminating details (e.g., no OSA, compensated hypercapnia, post-exacerbation stability) to identify nocturnal NIV as the single best step, with alternatives clearly inferior based on risks or lack of evidence. Main medical accuracy issues: none; aligns with GOLD guidelines and trials (e.g., HOT-HMV) showing NIV reduces mortality in this phenotype, while increasing oxygen risks worsening CO2 retention, chronic steroids cause harm, acetazolamide lacks robust long-term data, and HFNC offers comfort but not proven mortality benefits. Minimal fix: None required; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include severe COPD with FEV1 35% predicted, chronic hypercapnia (PaCO2 58 mm Hg, compensated pH 7.37, HCO3- 33 mEq/L), recent hypercapnic exacerbation requiring NIV, persistent daytime somnolence and morning headaches, sustained hypoventilation on overnight oximetry without obstructive apneas, and adherence to standard therapies with PaO2 70 mm Hg on 2 L/min oxygen. These point to chronic hypercapnic respiratory failure needing ventilatory support to improve mortality. Main logical issues: none; the stem provides sufficient discriminating details (e.g., no OSA, compensated hypercapnia, post-exacerbation stability) to identify nocturnal NIV as the single best step, with alternatives clearly inferior based on risks or lack of evidence. Main medical accuracy issues: none; aligns with GOLD guidelines and trials (e.g., HOT-HMV) showing NIV reduces mortality in this phenotype, while increasing oxygen risks worsening CO2 retention, chronic steroids cause harm, acetazolamide lacks robust long-term data, and HFNC offers comfort but not proven mortality benefits. Minimal fix: None required; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-008", "question": "A 59-year-old man with a history of MI and paroxysmal atrial fibrillation presents with acute-onset right eye visual loss described as a \"curtain\" descending over 10 minutes, now partially improved. Exam reveals a right relative afferent pupillary defect and patchy visual field deficit; neurologic exam is otherwise normal. He takes apixaban 5 mg twice daily, metoprolol, and atorvastatin, and reports strict adherence. BP is 130/72 mm Hg. MRI brain with DWI is normal; MRA head/neck shows no large-vessel occlusion or significant carotid stenosis. Fundoscopic exam shows retinal whitening in the inferior arcade consistent with branch retinal artery occlusion (BRAO). Which management strategy is most appropriate regarding his antithrombotic regimen?", "options": ["Continue apixaban and add aspirin 81 mg daily indefinitely", "Switch apixaban to warfarin with target INR 2.5-3.5", "Continue apixaban at the same dose without change", "Increase apixaban dose to 10 mg twice daily for 1 month, then 5 mg twice daily", "Discontinue anticoagulation and use dual antiplatelet therapy for 90 days"], "answer": "C", "answer_index": 2, "explanation": "BRAO in an anticoagulated AF patient is treated as a small ischemic stroke; however, there is no high-level evidence that switching DOACs, adding chronic antiplatelet therapy, or using higher-dose anticoagulation improves outcomes over continuing appropriate-dose DOAC once adherence and dosing are confirmed. Adding aspirin increases bleeding risk without proven benefit; warfarin or dual antiplatelets are not superior for AF-related events when DOAC therapy is adequate.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include history of paroxysmal atrial fibrillation (AF) on apixaban 5 mg twice daily with strict adherence, acute branch retinal artery occlusion (BRAO) confirmed by fundoscopy, normal MRI/MRA without large-vessel issues, and otherwise normal neurologic exam—implying a likely cardioembolic event despite anticoagulation, with no evidence of non-adherence, underdosing, or alternative etiologies requiring regimen change. Main logical issue(s): None; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting continuation of current DOAC as the single best strategy per standard guidelines. Main medical accuracy issue(s): None; the item's logic aligns with current AHA/ACC guidelines for AF management, treating BRAO as a small ischemic event where continuing appropriate DOAC is preferred over switching to warfarin, adding antiplatelets (increasing bleed risk without benefit), dose escalation (no evidence), or stopping anticoagulation (risky for AF). Minimal fix: None needed, as the item is unambiguous and accurate; optionally, add explicit confirmation of apixaban dosing appropriateness to further reinforce defensibility.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include history of paroxysmal atrial fibrillation (AF) on apixaban 5 mg twice daily with strict adherence, acute branch retinal artery occlusion (BRAO) confirmed by fundoscopy, normal MRI/MRA without large-vessel issues, and otherwise normal neurologic exam—implying a likely cardioembolic event despite anticoagulation, with no evidence of non-adherence, underdosing, or alternative etiologies requiring regimen change. Main logical issue(s): None; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting continuation of current DOAC as the single best strategy per standard guidelines. Main medical accuracy issue(s): None; the item's logic aligns with current AHA/ACC guidelines for AF management, treating BRAO as a small ischemic event where continuing appropriate DOAC is preferred over switching to warfarin, adding antiplatelets (increasing bleed risk without benefit), dose escalation (no evidence), or stopping anticoagulation (risky for AF). Minimal fix: None needed, as the item is unambiguous and accurate; optionally, add explicit confirmation of apixaban dosing appropriateness to further reinforce defensibility.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-009", "question": "A 46-year-old man presents with sudden severe tearing chest pain radiating to the back. BP is 210/110 mm Hg in both arms, HR 112/min. CT angiography shows an acute Stanford type B aortic dissection starting distal to the left subclavian artery and extending to the infrarenal aorta with involvement of the origin of the left renal artery, but no signs of rupture or pericardial effusion. The left kidney is perfused via a narrowed true lumen; creatinine is 1.4 mg/dL (baseline 1.0). There is no limb ischemia, mesenteric ischemia, or refractory pain after initial IV beta-blocker and vasodilator therapy, and BP is controlled to 115/70 mm Hg. Which management strategy is most appropriate now?", "options": ["Immediate thoracic endovascular aortic repair (TEVAR) to prevent late aneurysmal degeneration", "Open surgical repair of the descending thoracic aorta due to renal artery involvement", "Strict medical therapy with anti-impulse control and serial imaging", "Prophylactic left renal artery stenting plus medical therapy", "Fenestration and true lumen expansion with balloon angioplasty"], "answer": "C", "answer_index": 2, "explanation": "Uncomplicated type B aortic dissection without rupture, malperfusion, refractory pain, or uncontrolled hypertension is managed initially with aggressive medical therapy and surveillance. Renal artery involvement without clinical malperfusion or progressive renal dysfunction does not mandate immediate TEVAR or intervention; endovascular repair is reserved for complicated cases or aneurysmal progression on follow-up imaging.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include sudden severe tearing chest pain radiating to the back, BP 210/110 mm Hg, HR 112/min, CT showing acute Stanford type B aortic dissection distal to left subclavian artery extending to infrarenal aorta with left renal artery involvement but perfused via narrowed true lumen, creatinine 1.4 mg/dL (baseline 1.0), no rupture, pericardial effusion, limb/mesenteric ischemia, or refractory pain after BP control to 115/70 mm Hg with IV beta-blockers and vasodilators. These indicate an uncomplicated type B dissection, where strict medical therapy with anti-impulse control and serial imaging is the standard initial management per current guidelines (e.g., ACC/AHA). Main logical issue(s): None; the stem provides sufficient details to discriminate C as uniquely best without contradictions or underspecification. Alternatives are inferior: A assumes preventive TEVAR, not indicated acutely without complications; B favors open surgery, riskier and not first-line; D adds unnecessary prophylactic stenting without malperfusion; E suggests invasive fenestration, reserved for refractory cases. Main medical accuracy issue(s): None; aligns with mainstream standards emphasizing medical management for uncomplicated cases, reserving interventions for malperfusion or progression. Minimal fix: None required; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include sudden severe tearing chest pain radiating to the back, BP 210/110 mm Hg, HR 112/min, CT showing acute Stanford type B aortic dissection distal to left subclavian artery extending to infrarenal aorta with left renal artery involvement but perfused via narrowed true lumen, creatinine 1.4 mg/dL (baseline 1.0), no rupture, pericardial effusion, limb/mesenteric ischemia, or refractory pain after BP control to 115/70 mm Hg with IV beta-blockers and vasodilators. These indicate an uncomplicated type B dissection, where strict medical therapy with anti-impulse control and serial imaging is the standard initial management per current guidelines (e.g., ACC/AHA). Main logical issue(s): None; the stem provides sufficient details to discriminate C as uniquely best without contradictions or underspecification. Alternatives are inferior: A assumes preventive TEVAR, not indicated acutely without complications; B favors open surgery, riskier and not first-line; D adds unnecessary prophylactic stenting without malperfusion; E suggests invasive fenestration, reserved for refractory cases. Main medical accuracy issue(s): None; aligns with mainstream standards emphasizing medical management for uncomplicated cases, reserving interventions for malperfusion or progression. Minimal fix: None required; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-010", "question": "A 24-year-old man presents to the ED after being found confused and agitated. He reports taking an unknown \"research chemical\" for recreation. Vitals: T 40.1°C, HR 146/min, BP 178/104 mm Hg, RR 28/min, SpO2 96% RA. Exam shows mydriasis, diaphoresis, severe agitation with tremor, hyperreflexia, and inducible clonus, but no muscle rigidity. He is not taking prescription drugs and denies MAOI or SSRI use. Labs: Na 138, K 4.1, creatinine 1.0, CK 200 IU/L, normal LFTs. UDS is positive only for amphetamines. Despite high-dose benzodiazepines he remains agitated and hyperthermic. Which is the most appropriate next pharmacologic intervention?", "options": ["Intravenous dantrolene", "Intravenous cyproheptadine via crushed tablets", "Intravenous nitroprusside for blood pressure control alone", "Intravenous dexmedetomidine infusion", "Intravenous bromocriptine"], "answer": "D", "answer_index": 3, "explanation": "This is severe sympathomimetic (likely synthetic stimulant) toxicity with hyperthermia and agitation; there is hyperreflexia but the overall picture and isolated amphetamine screen favor stimulant rather than true serotonin syndrome. When benzodiazepines are insufficient, dexmedetomidine provides sympatholysis and sedation without worsening hyperthermia or respiratory drive as much as deep barbiturate or propofol sedation. Cyproheptadine and dantrolene target serotonin syndrome and NMS, respectively; bromocriptine is used in NMS and would exacerbate sympathomimetic effects.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 24-year-old with recreational 'research chemical' ingestion, presenting with confusion, agitation, hyperthermia (40.1°C), tachycardia (146/min), hypertension (178/104), tachypnea (28/min), mydriasis, diaphoresis, tremor, hyperreflexia, inducible clonus, but no muscle rigidity; UDS positive only for amphetamines, normal CK (200 IU/L), no SSRI/MAOI use; agitation and hyperthermia persist despite high-dose benzodiazepines. These point to sympathomimetic toxicity (e.g., synthetic stimulant) rather than serotonin syndrome (lacks rigidity and serotonergic triggers) or neuroleptic malignant syndrome (no rigidity, normal CK, no antipsychotics). The question asks for the most appropriate next pharmacologic intervention. Keyed answer D (IV dexmedetomidine) fits as it provides sympatholysis and sedation for refractory cases without significant respiratory depression. Alternatives: A (dantrolene) targets NMS/MH, incorrect without rigidity; B (IV cyproheptadine via crushed tablets) for SS, but lacks SS features and cyproheptadine is not standardly IV; C (nitroprusside) addresses BP alone, not agitation/hyperthermia; E (bromocriptine) for NMS, could worsen sympathomimetic effects. No main logical issues. Main medical accuracy issue: Option B inaccurately describes cyproheptadine as IV via crushed tablets, as it's typically oral only. Minimal fix: Revise option B to 'Oral cyproheptadine'.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 24-year-old with recreational 'research chemical' ingestion, presenting with confusion, agitation, hyperthermia (40.1°C), tachycardia (146/min), hypertension (178/104), tachypnea (28/min), mydriasis, diaphoresis, tremor, hyperreflexia, inducible clonus, but no muscle rigidity; UDS positive only for amphetamines, normal CK (200 IU/L), no SSRI/MAOI use; agitation and hyperthermia persist despite high-dose benzodiazepines. These point to sympathomimetic toxicity (e.g., synthetic stimulant) rather than serotonin syndrome (lacks rigidity and serotonergic triggers) or neuroleptic malignant syndrome (no rigidity, normal CK, no antipsychotics). The question asks for the most appropriate next pharmacologic intervention. Keyed answer D (IV dexmedetomidine) fits as it provides sympatholysis and sedation for refractory cases without significant respiratory depression. Alternatives: A (dantrolene) targets NMS/MH, incorrect without rigidity; B (IV cyproheptadine via crushed tablets) for SS, but lacks SS features and cyproheptadine is not standardly IV; C (nitroprusside) addresses BP alone, not agitation/hyperthermia; E (bromocriptine) for NMS, could worsen sympathomimetic effects. No main logical issues. Main medical accuracy issue: Option B inaccurately describes cyproheptadine as IV via crushed tablets, as it's typically oral only. Minimal fix: Revise option B to 'Oral cyproheptadine'.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}]